Summit Therapeutics Share Discussion Threads

[waterloo01] 06/9/2018 18:04

It will definitely get spent.

Antibiotics have been a poor relation in pharma of late, something mentioned in the presentation and the need to make both an economic case and show superiority rather than just equivalence is an essential part of the trial design.

RDZ has continued to behave exactly as predicted from lab to patients and has a very good chance of repeating that in the phase 3. It was always the 'back up' drug to the high risk utrophin approach in DMD and seen as low risk.

[nobbygnome] 06/9/2018 17:50

Valuing a company on cash is ridiculous IMHO as sure as eggs are eggs most of it will be spent.......

Ho hum

[kirk 6] 06/9/2018 17:41

What sort of price would this get taken out at

[waterloo01] 06/9/2018 17:38

I expect this to trade closer to £1.00 in the coming months as while the cash is close to current market cap, that doesn't take into account the potential $62m ($32m currently committed) from Barda alone, plus other grants that they seem well linked into. At the least I think the share price should reflect that.

It would only take a few bad stories of resistance and hopefully the money will flow (unless it gets taken out before then).

[chrisatrdg] 06/9/2018 17:18

Q&A cut off I think was caused by the delay in starting so it timed out at end of slot hopefully the saved version will have further Q&A questions at least things have been made clearer on the production problem for the C-Diff drug which now seems resolved.

I do not think todays presentation & recent RNS's are going to move the market I think we are in for the long haul for share price recovery say once they have started the C-Diff trials next year.

[waterloo01] 06/9/2018 16:50

Seem to have cut off the Q&A on broadcast.

[multiplural] 06/9/2018 16:23

My guess is this company is not around in 2021, will be bought long before that.

[multiplural] 06/9/2018 16:19

My guess is this company is not around in 2021, will be bought long before that.

[waterloo01] 06/9/2018 16:17

Slide 24 shows the timeline. 2021/22 for the most important read outs. Cash stated as end April, so will have to wait for results for more up to date number.

[phowdo] 06/9/2018 16:17

Yet its heading lower stateside...

[multiplural] 06/9/2018 16:09

Have a look at slide 14 and 26 of the deck to be presented. Slide 14 shows Ridinilazols superiority and slide 26 shows the cash is higher than market cap. These two slides should in itself get this stock price moving balistic imo.

[chrisatrdg] 06/9/2018 14:52

I am logged in for the presentation who else will be taking part?

[waterloo01] 06/9/2018 13:33

RDZ remains the advanced and ready run phase 3 trial. What however is coming out of the Discuva purchase is very encouraging. Good buy only last year and prescient given the failure in DMD.

Current cash will be key in the short term. Hopefully it's over £20m mark.

[chrisatrdg] 06/9/2018 13:03

If you want a potted history on Discuva follow it on their Old twitter account - see below which ceased when bought by Summit it does go back a number of years.It is quite fascinating & hopefully will not be taken down.

[chrisatrdg] 06/9/2018 12:23

Hi someuwin I was amazed to see another RNS which seems as significant if not more so in the long run than yesterdays.It will be a interesting afternoon & this time I am looking forward to the Q&A session at the end.You never know the share price might even move up.

[solomon] 06/9/2018 12:22

David Roblin must be over the moon. Hopefully the share price will follow him!

[someuwin] 06/9/2018 12:20

Excellent news.

Multiple New Mechanism Antibiotics Against Superbugs.

[chrisatrdg] 06/9/2018 12:13

RNS Today

Summit Discovers Multiple New Mechanism Antibiotics Against Novel ESKAPE Pathogen Targets

Thu, 6 Sep 2018 12:00

Summit Therapeutics plc ([e-mail])

To:you Details

Summit Discovers Multiple New Mechanism Antibiotics Against Novel ESKAPE Pathogen Targets


Summit Therapeutics plc
(‘Summit’; or the ’Company’;)
Summit Discovers Multiple New Mechanism Antibiotics Against Novel ESKAPE Pathogen Targets

Discovery Enabled by Discuva Platform and Proprietary Bacterial Libraries
Oxford, UK, and Cambridge, MA, US, 6 September 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, announced today the discovery of multiple new mechanism antibiotics against novel ESKAPE pathogen targets. Commonly referred to as superbugs, the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp.) collectively comprise the leading cause of hospital-acquired infections globally. New classes of antibiotics are urgently needed to address these pathogens that are increasingly developing resistance to existing antibiotic drug classes.

“We believe we are building a very different antibiotics company that focuses on bringing innovation to an area of high unmet need. With new science, we believe the threat of ESKAPE pathogens and other serious infectious diseases can potentially be solved,” commented Mr Glyn Edwards, Chief Executive Officer of Summit. “At the core of our innovation is our powerful Discuva Platform. The platform allows us to uncover possible new ways to combat the potentially deadly ESKAPE pathogens. We can then aim to exploit this knowledge through the discovery and development of targeted new mechanism antibiotics.”

Summit’s Discuva Platform utilises proprietary libraries of mutant bacteria to identify genes which are essential for bacteria to survive. Summit’s libraries provide coverage across the ESKAPE pathogens. Through the Discuva Platform, Summit has identified essential ESKAPE pathogen genes, which could represent novel drug targets against these pathogens. Several of these targets are now the focus of Summit’s drug development programmes, with the platform having already discovered potential new mechanism antibiotics against them.

“We believe the identification of novel targets gives us the potential to develop the right drugs for the right bacteria, infection and patient. That would enable us to ensure that our antibiotics truly meet the needs of patients, their treating physicians and healthcare providers and to promote antibiotic stewardship,” added Dr David Roblin, President of R&D of Summit. “We believe this approach will afford us the opportunity to replace the current standards of care for these serious infections caused by the ESKAPE pathogens and bring potentially life-saving treatments to patients.”

About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients, and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for C. difficile infection and gonorrhoea and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (MAR).

Contacts

Summit
Glyn Edwards / Richard Pye (UK office) Tel: [phone]
Erik Ostrowski / Michelle Avery (US office) [phone]

Cairn Financial Advisers LLP (Nominated Adviser) Tel: [phone]
Liam Murray / Tony Rawlinson

N+1 Singer (Joint Broker) Tel: [phone]
Aubrey Powell / Jen Boorer, Corporate Finance
Tom Salvesen, Corporate Broking

Panmure Gordon (Joint Broker) Tel: [phone]
Freddy Crossley, Corporate Finance
James Stearns, Corporate Broking

MSL Group (US) Tel: [phone]
Jon Siegal [e-mail]

Consilium Strategic Communications (UK) Tel: [phone]
Mary-Jane Elliott / Jessica Hodgson / [e-mail]
Lindsey Neville
Summit Forward-looking Statements

Any statements in this press release about the Company’s future expectations, plans and prospects, including but not limited to, statements about the potential benefits of the CARB-X award, including whether the option segments will be exercised, the clinical and preclinical development of the Company’s product candidates, the therapeutic potential of the Company’s product candidates, the potential commercialisation of the Company’s product candidates, the sufficiency of the Company’s cash resources, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" section of filings that the Company makes with the Securities and Exchange Commission, including the Company’s Annual Report on Form 20-F for the fiscal year ended 31 January 2018. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of this release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.

-END-

[freedosh] 05/9/2018 12:56

Go to the related articles section at the bottom of that article and check out “curbing drug resistance” from KPMG. Not new and discusses neither C.Diff nor gonorrhoea but puts the issue in eye watering context and potential cost.